1259330-30-7Relevant articles and documents
Discovery of [1,2,4]Triazolo[1,5- a]pyridine Derivatives as Potent and Orally Bioavailable RORγt Inverse Agonists
Nakajima, Ryota,Oono, Hiroyuki,Sugiyama, Sakae,Matsueda, Yohei,Ida, Tomohide,Kakuda, Shinji,Hirata, Jun,Baba, Atsushi,Makino, Akito,Matsuyama, Ryo,White, Ryan D.,Wurz, Ryan P.,Shin, Youngsook,Min, Xiaoshan,Guzman-Perez, Angel,Wang, Zhulun,Symons, Antony,Singh, Sanjay K.,Mothe, Srinivasa Reddy,Belyakov, Sergei,Chakrabarti, Anjan,Shuto, Satoshi
, p. 528 - 534 (2020)
The retinoic acid receptor-related orphan nuclear receptor γt (RORγt), a promising therapeutic target, is a major transcription factor of genes related to psoriasis pathogenesis such as interleukin (IL)-17A, IL-22, and IL-23R. On the basis of the X-ray cocrystal structure of RORγt with 1a, an analogue of the known piperazine RORγt inverse agonist 1, triazolopyridine derivatives of 1 were designed and synthesized, and analogue 3a was found to be a potent RORγt inverse agonist. Structure-activity relationship studies on 3a, focusing on the treatment of its metabolically unstable cyclopentyl ring and the central piperazine core, led to a novel analogue, namely, 6-methyl-N-(7-methyl-8-(((2S,4S)-2-methyl-1-(4,4,4-trifluoro-3-(trifluoromethyl)butanoyl)piperidin-4-yl)oxy)[1,2,4]triazolo[1,5-a]pyridin-6-yl)nicotinamide (5a), which exhibited strong RORγt inhibitory activity and a favorable pharmacokinetic profile. Moreover, the in vitro and in vivo evaluation of 5a in a human whole-blood assay and a mouse IL-18/23-induced cytokine expression model revealed its robust and dose-dependent inhibitory effect on IL-17A production.
CHEMICAL COMPOUNDS
-
, (2011/12/04)
The present invention relates to certain substituted picolinic acid derivatives, as well as N- oxides and agriculturally acceptable salts thereof, and their use in controlling plant growth, particularly undesirable plant growth, in crops of useful plants. The invention extends to herbicidal compositions comprising such compounds, N-oxides and/or salts as well as mixtures of the same with one or more further active ingredients and/or a safener.
